Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) ##STR00001## or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.q, R.sup.w, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.